Published Thu, 09 Dec 2010 13:05 CET by TopYields.nl
Japanese researchers of Tokyo's Keio University have succeeded in restoring partial mobility in a small monkey that had been paralysed from the neck down by a spinal injury (Inquirer.net).
The injection of iPS cells was given on the ninth day after the injury and the monkey started to move its limbs again within two to three weeks. After six weeks, the monkey was jumping around and close to the normal level.
In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues. Stem cells can be grown and transformed into specialized cells with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture.
So, how does this breaking news gives us an investment opportunity? Well, meet Cryo-Save. The Cryo-Save Group N.V. (Euronext Amsterdam: CRYO, ISIN NL0009272137) is Europe's largest adult stem cell storage bank, with more than 140,000 samples stored. The company was established in 2000, is headquartered in The Netherlands and owns or has access to operating laboratory and storage facilities in Belgium, Germany, Dubai, India and France.
Cryo-Save is focused on the collection and storage of ADULT (not embryonic) stem cells derived from cord blood, umbilical and adipose tissue.
Cryo-Save is currently trading at EUR 4.90, with an intrinsic value of EUR 4.54 per share. The P/E is fairly high, around 33. Cryo-Save has a dividend of EUR 0.06 per share, which means a dividend yield of 1.2%.
Disclosure: at the moment of writing, TopYields owns 200 Cryo-Save shares.
Stock symbol(s): CRYO.AS
|Stock name||ISIN||Last trade||P/E||EPS||Div PS||Ex Div Date||Payout Ratio||Div Yield|
|CRYO SAVE||NL0009272137||1.83||0.0||-0.2||0.07||May 18 2012||-30||3.72|